AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Beta Bionics, Inc. Director's Dealing 2025

Jan 30, 2025

32351_dirs_2025-01-29_04905737-5942-4433-ae24-b1585449a40f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Beta Bionics, Inc. (BBNX)
CIK: 0001674632
Period of Report: 2025-01-29

Reporting Person: CARNEY SEAN (N/A)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Director Stock Option (right to buy)	$7.51	2030-05-14	Class B Common Stock (55837)		Direct
Director Stock Option (right to buy)	$7.51	2032-07-26	Class B Common Stock (30456)		Direct

Footnotes

F1: The shares subject to this option shall vest in 36 equal monthly installments measured from February 12, 2020.

F2: In accordance with the Issuer's Amended and Restated Certificate of Incorporation, the Issuer's outstanding shares of Class B Common Stock will convert into an equal number of shares of Common Stock immediately prior to the closing of the initial public offering.

F3: The shares subject to this option shall vest in 36 equal monthly installments measured from July 27, 2022.